This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Dynavax Technologies Corporation, Trisalus Life Sciences, Inc.. Active years: 2020-2024.
Company Filing History:
2 out of 2,405 
1 out of 66 
1 out of 18 Years Active: 2020-2024
Title: Innovations by Inventor Ying Yu
Introduction
Ying Yu is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of cancer treatment through his innovative research and development of combination therapies. With a total of two patents to his name, his work focuses on enhancing the efficacy of cancer therapies.
Latest Patents
Ying Yu's latest patents include a combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer. This patent describes combination therapies that comprise an antagonist of the Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist, specifically a CpG-C type oligonucleotide. The disclosure emphasizes the use of these combination therapies for the treatment of cancer, showcasing the potential for improved patient outcomes.
Career Highlights
Throughout his career, Ying Yu has worked with prominent companies in the biotechnology and pharmaceutical sectors. Notably, he has been associated with Merck Sharp & Dohme Corporation and Dynavax Technologies Corporation. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.
Collaborations
Ying Yu has collaborated with several professionals in his field, including Andrew Evan Denker and Svetlana Sadekova. These collaborations have likely enriched his research and development efforts, leading to advancements in cancer treatment.
Conclusion
Ying Yu's contributions to cancer therapy through his innovative patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for new treatment options that may improve the lives of cancer patients.